The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma. 2015

Ying Guan, and Anchuan Li, and Weiwei Xiao, and Shuai Liu, and Binbin Chen, and Taixiang Lu, and Chong Zhao, and Fei Han
Department of Radiotherapy Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, P. R. China.

OBJECTIVE To evaluate the short-term efficacy and safety of recombinant human endostatin (Endostar) combined with chemoradiotherapy for the treatment of advanced, locally recurrent nasopharyngeal carcinoma (NPC). METHODS Between March 2010 and October 2013, a total of 22 patients with stage rIII-IVb locally recurrent NPC underwent salvage radiotherapy with Endostar in Sun Yat-Sen University Cancer Center. Intensity-modulated radiotherapy (IMRT) was delivered. Platinum-based chemotherapy was used in a neoadjuvant protocol. Endostar was continuously administered intravenously (105 mg/m2) for 14 days (Days 1-14) from the first day of treatment during a 21-day cycle. Tumor response and treatment toxicities were observed. RESULTS Until January 2014, the median follow-up time was 13 months (range, 4-41 months). All patients completed the planned radiotherapy. A complete response was achieved in 20 patients, and a partial response was achieved in 2 patients. The incidence of grade 3-5 late radiation injury in this study was 50% (11/22) and that of nasopharyngeal mucosal necrosis was 31.8% (7/22). CONCLUSIONS Endostar combined with chemoradiotherapy may be effective in decreasing both the incidence of nasopharyngeal mucosal necrosis. Studies with a larger sample size and longer follow-up are warranted.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009303 Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX. Cancer of Nasopharynx,Nasopharyngeal Cancer,Cancer of the Nasopharynx,Nasopharynx Cancer,Nasopharynx Neoplasms,Neoplasms, Nasopharyngeal,Cancer, Nasopharyngeal,Cancer, Nasopharynx,Cancers, Nasopharyngeal,Cancers, Nasopharynx,Nasopharyngeal Cancers,Nasopharyngeal Neoplasm,Nasopharynx Cancers,Nasopharynx Neoplasm,Neoplasm, Nasopharyngeal,Neoplasm, Nasopharynx,Neoplasms, Nasopharynx
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

Ying Guan, and Anchuan Li, and Weiwei Xiao, and Shuai Liu, and Binbin Chen, and Taixiang Lu, and Chong Zhao, and Fei Han
July 2022, Radiation oncology (London, England),
Ying Guan, and Anchuan Li, and Weiwei Xiao, and Shuai Liu, and Binbin Chen, and Taixiang Lu, and Chong Zhao, and Fei Han
January 2022, Oncology research,
Ying Guan, and Anchuan Li, and Weiwei Xiao, and Shuai Liu, and Binbin Chen, and Taixiang Lu, and Chong Zhao, and Fei Han
January 2021, Frontiers in oncology,
Ying Guan, and Anchuan Li, and Weiwei Xiao, and Shuai Liu, and Binbin Chen, and Taixiang Lu, and Chong Zhao, and Fei Han
January 2012, Asian Pacific journal of cancer prevention : APJCP,
Ying Guan, and Anchuan Li, and Weiwei Xiao, and Shuai Liu, and Binbin Chen, and Taixiang Lu, and Chong Zhao, and Fei Han
November 2021, BMC cancer,
Ying Guan, and Anchuan Li, and Weiwei Xiao, and Shuai Liu, and Binbin Chen, and Taixiang Lu, and Chong Zhao, and Fei Han
September 2022, Medicine,
Ying Guan, and Anchuan Li, and Weiwei Xiao, and Shuai Liu, and Binbin Chen, and Taixiang Lu, and Chong Zhao, and Fei Han
November 2021, Annals of palliative medicine,
Ying Guan, and Anchuan Li, and Weiwei Xiao, and Shuai Liu, and Binbin Chen, and Taixiang Lu, and Chong Zhao, and Fei Han
February 2015, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Ying Guan, and Anchuan Li, and Weiwei Xiao, and Shuai Liu, and Binbin Chen, and Taixiang Lu, and Chong Zhao, and Fei Han
January 2013, Tumori,
Ying Guan, and Anchuan Li, and Weiwei Xiao, and Shuai Liu, and Binbin Chen, and Taixiang Lu, and Chong Zhao, and Fei Han
January 2020, Journal of biological regulators and homeostatic agents,
Copied contents to your clipboard!